408 results on '"Kasi, Pashtoon Murtaza"'
Search Results
2. Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
3. Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update.
4. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers
5. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes
6. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
7. Feasibility of implementing whole genome sequencing into routine oncology care.
8. Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).
9. Chapter 14 - Circulating tumor DNA (ctDNA) as a new and evolving tool in solid organ transplantation
10. Liquid biopsies and tumor mutational burden: the cutoff conundrum
11. Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies
12. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.
13. Patient-reported outcomes from the BESPOKE CRC study.
14. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.
15. Rising Proportion of Young Individuals With Rectal and Colon Cancer
16. IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms
17. False-Positive Liquid Biopsy Assays Secondary to Overlapping Aberrant Methylation from Non-Cancer Disease States
18. Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies
19. Editorial: Case reports in gastrointestinal cancers : 2022
20. Vector control in cutaneous leishmaniasis of the old world: A review of literature
21. Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
22. Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma
23. Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy
24. Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial).
25. Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
26. List of contributors
27. Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer
28. DPYD Testing: Time to Put Patient Safety First
29. Circulating tumor cells (CTCs) as liquid biopsies in patients with metastatic colorectal cancer versus other GI malignancies.
30. Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.
31. HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial.
32. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.
33. Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis.
34. Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer.
35. Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
36. Liquid biopsy detection of tumor shed in cancers for which molecular profiling is best practice.
37. Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension
38. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
39. Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
40. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
41. Using cell-free circulating tumor DNA (cfDNA) to identify guideline-relevant biomarkers for therapy selection in 14,000 patients (pts) with metastatic colorectal cancer (mCRC).
42. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
43. Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte® Platform
44. Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).
45. Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.
46. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
47. A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.
48. Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.
49. The role of serial analysis of hepatocellular carcinoma via circulating tumor DNA in identification of new actionable alterations.
50. A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.